Azalea Therapeutics
Azalea Therapeutics is a biotechnology company redefining precision genomic medicines in vivo. Its proprietary Enveloped Delivery Vehicles (EDV) platform is engineered to deliver transient CRISPR-Cas9 cargo to specific cells in the body for site-specific genome editing with curative intent. Azalea’s first programs leverage T cell-targeting EDVs and highly efficient T cell-tropic AAVs to enable programmable CAR gene insertion at a defined genomic locus, placing expression under control of the cell’s endogenous promoter for physiologic and sustained activity.
Leadership & Board
- Current Number of Employees
- 34
- Current LinkedIn Followers
- 6,583
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $82M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $82M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Azalea Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce size remains relatively unchanged.
Employee Trend
Azalea Therapeutics had 34 employees as of October 12, 2026. The number of employees decreased by 1 (2.86%) week-over-week.
Social Trend
Azalea Therapeutics had 6,583 followers as of October 12, 2026. The number of followers increased by 177 (2.76%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 04, 2025 | Series A | $82.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| RA Capital Management | Series A |
| Yosemite | Series A |
| Sozo Ventures | Series A |
| Third Rock Ventures | Series A |
Similar Companies
A snapshot of private companies similar to Azalea Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
